Literature DB >> 14666709

Protein kinase C eta is associated with progression of renal cell carcinoma (RCC).

Walburgis Brenner1, Gloria Färber, Thomas Herget, Christoph Wiesner, Jan G Hengstler, Joachim W Thüroff.   

Abstract

BACKGROUND: The expression of all eleven PKC-isoforms in clear cell RCCs (ccRCC) and in the corresponding normal renal tissue was quantified. A possible association of PKC-isoforms with histopathological parameters was examined.
MATERIALS AND METHODS: Proteins were isolated from tumor and normal tissue of 43 patients with ccRCC. Expression of PKC-isoforms were quantified by Western blot analysis.
RESULTS: In both, ccRCCs and the corresponding normal renal tissue, all PKC-isoforms apart from PKC gamma and theta were detectable. Striking associations between PKC-isoforms and histopathological parameters were observed: (i) a 3-fold increase in PKC eta of grade 3 and 4 versus grade 1 and 2 tumors (p = 0.025), (ii) a decrease of PKC alpha in tumor versus normal tissue of 18% (p = 0.020) and (iii) a 20% increase of PKC zeta in grade 3 and 4 versus grade 1 and 2 tumors (p = 0.092).
CONCLUSION: The major result is a clear correlation of PKC eta expression with tumor progression. This observation-is in agreement with the known oncogenic properties of PKC eta. Similarly, oncogenic PKC zeta also increased with tumor progression. PKC alpha, with known tumor-suppressor properties, was decreased in ccRCC versus normal tissue. These findings may become important for both classification and treatment of ccRCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666709

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  [Kidney tumors].

Authors:  J W Thüroff
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 2.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

3.  Adhesion of renal carcinoma cells to endothelial cells depends on PKCmu.

Authors:  Walburgis Brenner; Silke Beitz; Elke Schneider; Frank Benzing; Ronald E Unger; Frederik C Roos; Joachim W Thüroff; Christian Hampel
Journal:  BMC Cancer       Date:  2010-05-06       Impact factor: 4.430

4.  Upregulation of PKCη by PKCε and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival.

Authors:  Deepanwita Pal; Shalini Persaud Outram; Alakananda Basu
Journal:  Biochim Biophys Acta       Date:  2013-04-04

5.  The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity.

Authors:  Elisabeth Ersvaer; Astrid Olsnes Kittang; Peter Hampson; Kristoffer Sand; Bjørn Tore Gjertsen; Janet M Lord; Oystein Bruserud
Journal:  Toxins (Basel)       Date:  2010-01-22       Impact factor: 4.546

6.  A genome-wide approach to identify genetic loci with a signature of natural selection in the Irish population.

Authors:  Valeria Mattiangeli; Anthony W Ryan; Ross McManus; Daniel G Bradley
Journal:  Genome Biol       Date:  2006-08-11       Impact factor: 13.583

7.  miR-24-3p Suppresses Malignant Behavior of Lacrimal Adenoid Cystic Carcinoma by Targeting PRKCH to Regulate p53/p21 Pathway.

Authors:  Ming-Xue Zhang; Jie Zhang; Hong Zhang; Hua Tang
Journal:  PLoS One       Date:  2016-06-28       Impact factor: 3.240

8.  Integrin α5 triggers the metastatic potential in renal cell carcinoma.

Authors:  Dirk Prawitt; Walburgis Brenner; Ines Breuksch; Franz Prosinger; Fabian Baehr; Franz-Peter Engelhardt; Heide-Katharina Bauer; Joachim W Thüroff; Anne-Sophie Heimes; Annette Hasenburg
Journal:  Oncotarget       Date:  2017-11-18

9.  Differentially expressed autophagy-related genes are potential prognostic and diagnostic biomarkers in clear-cell renal cell carcinoma.

Authors:  Bangbei Wan; Bo Liu; Gang Yu; Yuan Huang; Cai Lv
Journal:  Aging (Albany NY)       Date:  2019-10-17       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.